Table 1 |
||||
|
Demographic, clinical, and laboratory characteristics of patients with psoriatic arthritis, rheumatoid arthritis, and controls |
||||
| Characteristic |
Psoriatic arthritis |
Rheumatoid arthritis (group I) |
Matched rheumatoid arthritis (group II) |
Controls |
|
|
||||
| Number of patients |
15 |
49 |
30 |
8 |
| Age (years) |
55.7 ± 10.7 |
57.6 ± 14.6 |
56.3 ± 16.3 |
38.1 ± 21.9 |
| Sex (women/men)* |
8/7 |
42/7 |
20/10 |
4/4 |
| Disease duration (months) |
63.5 ± 62.7 |
93.5 ± 98.7 |
78.2 ± 86.2 |
NA |
| Morning stiffness (minutes) |
70.4 ± 55.7 |
96.2 ± 96.3 |
76.8 ± 92.1 |
NA |
| Number of tender joints* |
8.0 ± 5.5 |
13.7 ± 9.4 |
9.1 ± 7.3 |
0 |
| Number of swollen joints |
5.3 ± 4.4 |
8.0 ± 5.8 |
5.0 ± 3.9 |
0 |
| Ritchie index |
8.3 ± 5.7 |
11.6 ± 6.9 |
7.0 ± 5.1 |
0 |
| ESR (mm/h) |
34.7 ± 21.8 |
49.1 ± 31.6 |
45.5 ± 35.7 |
ND |
| CRP (mg/l) |
30.4 ± 39.4 |
30.3 ± 34.4 |
26.6 ± 36.1 |
ND |
| Number of patients with IgM rheumatoid factor** |
1 (6.7%) |
33 (67.3%) |
18 (60%) |
ND |
| Rate of early enhancement§ |
1.0 ± 0.6 |
1.6 ± 0.7 |
1.3 ± 0.7 |
0.1 ± 0.1 |
| Relative enhancement § |
87.1 ± 39.2 |
125.8 ± 48.0 |
107.3 ± 48.2 |
15.5 ± 19.2 |
|
|
||||
|
Values are expressed as means ± standard deviations except for sex and IgM rheumatoid factor, for which the percentage of positive patients is reported. *P < 0.05 for the comparison between PsA and groupI RA; **P < 0.001 for the comparison between PsA and groupI RA and P < 0.05 for the comparison between PsA and groupII RA; §P < 0.001 by one-way analysis of variance between PsA patients, groupI RA patients, and controls. |
||||
|
Cimmino et al. Arthritis Research & Therapy 2005 7:R725 doi:10.1186/ar1734 |
||||
